RussianPatents.com

Pharmaceutical compositions for depression and anxiety disorder (versions). RU patent 2449804.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, particularly a pharmaceutical composition for depression and anxiety disorder (versions). Pharmaceutical composition for at least one of depression and anxiety disorder containing ginsenoside Rg1 and Rb1; a glycyrrhizic acid derivative being an acid specified in a group consisting of glycyrrhizic acid, glycyrrhetinic acid and combinations thereof; and cyclic adenosine monophosphate of jojoba (cAMP of jojoba), taken in certain amount. The pharmaceutical composition for treating at least one of depression and anxiety disorder containing ginsenoside Rg1 and Rb1; and a glycyrrhizic acid derivative being specified in a group consisting of glycyrrhizic acid, glycyrrhetinic acid and their combination taken in specific proportions.

EFFECT: compositions are effective for treating depression and anxiety disorder.

7 cl, 6 dwg, 19 tbl

IPC classes for russian patent Pharmaceutical compositions for depression and anxiety disorder (versions). RU patent 2449804. (RU 2449804):

A61P25/24 - Antidepressants

A61P25/22 - Anxiolytics

A61K36/725 - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J0003000000; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L)

A61K36/484 - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J0003000000; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L)

A61K36/258 - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J0003000000; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L)

Another patents in same IPC classes:

Novel derivatives of 1,3-dihydro-5-isobenzofurancarbonitryl and based on them pharmaceutical composition for treating premature ejaculation / 2448963
Invention relates to novel derivatives of 1,3-dihydro-5-isobenzofurancarbonyl of formula 1, or their pharmaceutically acceptable salts, where R1 represents phenyl, phenyl substituted with C1-C6-alkyloxy, phenyl, substituted with C1-C6-alkyl, phenyl, substituted with C1-C6-dialkylamine, phenyl, substituted with halogen or thienyl; R2 is selected from group consisting of C1-C6-dialkylamino, pyrazolyl and imidazolyl, excluding C1-C6-dialkylamino, if R1 represents phenyl, phenyl substituted with halogen; n represents integer number from 1 to 3, and method of their obtaining.

Method of treating and improving quality of life in patients with chronic pancreatitis / 2448675
Invention refers to medicine, particularly gastoenterology, reflexotherapy, physiotherapy. It involves a conventional drug-induced therapy of chronic pancreatitis. It is added with the antidepressant azaphen 75 mg daily in clinically apparent affective disorders, 50 mg daily in subclinically apparent affective disorders for 30 days. Magnetic laser puncture is performed with considering a vegetative balance state. One biologically active point is exposed to modulated wave length 1.3 mcm, frequency 2.4 Hz, magnetic induction 50 mT for 10-30 seconds. Sympathicotonia requires sequential sedation of the point GI 4 and toning of the points. E 25, E 36, MC 6. Vagotonia requires toning of the point GI 4 and sedation of the points E 25, E 36, MC 6. It is accompanied with transcutaneous magnetic laser exposure at wave length 0.89 mcm with using a magnetic tip 150 mT. A solar plexus area, a projection of pancreas, a projection of gall bladder are covered for 2 minutes. In manifested pain syndrome, the exposure starts at the frequency of 820 Hz to be decreased to 80 Hz. In weak pain syndrome, the frequency of 360 Hz is gradually decreased to 80 Hz. In the absence of pain syndrome, the exposure is applied at the frequency of 80 Hz.

Use of 5-methyl-1,3-benzdiol or its derivatives in preparing drug and functional food stuff for treating and preventing depression / 2447887
Invention refers to pharmaceutics and medicine and concerns the use of 3,5-dihydroxytoluene or its derivatives for preparing drugs and functional food stuff for treating or preventing depression.

Substituted methyl-amines, serotonin 5-ht<sub>6</sub> receptor antagonists, methods of production and use

Substituted methyl-amines, serotonin 5-ht₆ receptor antagonists, methods of production and use / 2443697
Invention relates to novel substituted methyl-amines of general formula 1, having serotonin 5-HT6 receptor antagonist properties. In formula 1 , W is naphthalene, indolysin or quinoline; R1 is hydrogen, fluorine, chlorine, methyl; R2 is hydrogen, fluorine, methyl, phenyl, thiophen-2-yl, furan-2-yl, pyridyl, piperazin-1-yl or 4-methylpiperazin-1-yl; R3 is methyl; or W is benzene, R3 assumes the value given above; R1 is 3-Cl, R2 is 3-piperazin-1-yl or 3-(4-methylpiperazin-1-yl); or R1 is hydrogen, R2 is phenyl or pyridyl; or R1 is hydrogen, fluorine, chlorine, methyl; R2 is 4-piperazin-1-yl or 4-(4-methylpiperazin-1-yl); or W is oxazole, R3 is optionally substituted methyl; R1 is chlorine or fluorine, R2 is methyl, or R1 is hydrogen, fluorine, chlorine, methyl; R2 is piperazin-1-yl, 4-methylpiperazin-1-yl, or R1 is chlorine, fluorine or methyl; R2 is furan-2-yl, or R1 is hydrogen, fluorine, chlorine, methyl; R2 is furan-2-yl, R3 is (tetrahydrofuran-2-yl)methyl, or R1 is hydrogen, fluorine, chlorine, methyl; R2 is thiophen-2-yl, R3 is 2-methoxyethyl, or R1 is chlorine or fluorine, R2 is thiophen-2-yl, R3 is methyl.

Method of treating and increasing quality of patients with gallbladder dyskinesia / 2440807
Invention relates to medicine, namely to gastroenterology, physiotherapy, rexlexotherapy. Method includes carrying out drug therapy. Additionally, taking into account degree of expression of anxiety-depressive disorders by Hamilton scale data, antidepressant asaphen is introduced. In case of clinically expressed disorders asaphen is introduced in dose 75 mg per day, in case of subclinically expressed affective disorders - in dose 50 mg per day. Intake of asaphen is realised during 30 days. Taking into account individual peculiarities of vegetative balance state magnetic laser puncture is performed. For this purpose used is wavelength 1.3 mcm, modulated mode, frequency 2.4 Hz, magnetic-acupuncture nozzle 50 mT. Impact is carried out during 10-30 s per one biologically active point. In case of sympathicotonia point Gl 4 is sedated and points E 25, E 36, MC 6 are toned up. In case of vagotonia point Gl 4 is toned up and points E 25, E 36, MC 6 are sedated. Course includes 10-12 procedures.

Medication possessing antidepressive, anxiolytic and nootropic action / 2437659
Invention relates to pharmaceutical industry and medicine. Claimed is application of N-carbamoyl-4-(n-methoxyphenyl)-2-pyrrolidone of structural formula as means possessing antidepressive, anxiolytic and nootropic action. This low-toxic compound (LD50 2263.88 mg/kg) possesses high antidepressive, anxiolytic and nootropic activity, affect of which is not accompanied by hypnosedative phenomena, or reduction of mental and physical work ability.

Thiophenyl and pyrrolyl azepines as serotonin 5ht<sub>2c</sub> receptor ligands and use thereof

Thiophenyl and pyrrolyl azepines as serotonin 5ht_2c receptor ligands and use thereof / 2434872
Invention relates to compounds of formula , where X denotes S; R1 and R2 taken together with atoms to which they are bonded form a 5-member carbocycle, substituted with up to two substitutes selected from alkyl and CF3; R3 is selected from a group consisting of a hydrogen atom and C1-8-alkyl; R3a denotes a hydrogen atom; R4 denotes a hydrogen atom; R4a denotes a hydrogen atom; R5 denotes a hydrogen atom; R5a denotes a hydrogen atom; R6 denotes a hydrogen atom; R6a denotes a hydrogen atom; R7 denotes a hydrogen atom; or pharmaceutically acceptable salts thereof. The invention also relates to compounds of the given formula, compounds selected from the group, as well as a pharmaceutical composition.

Cycloalkylamines as monoamine reuptake inhibitors / 2430913
Invention relates to novel cyclohexylamine derivatives of formula (I), having inhibiting properties towards at least one monoamine transporter, such as serotonin transporter, dopamine transporter or norepinephrine transporter, or a combination of two or more transporters. The compounds can be used to treat and/or prevent central nervous system disorders such as pain, depression, anxiety, schizophrenia, sleep disorder etc. In formula (I) , n equals 0 or 1; s equals 1, 2 or 3, m equals a whole number from 0 to 12; Ar is

S-adenosylmethionine compositions for peroral application / 2427376
Claimed are dietary and/or nutriceutic pharmaceutical composition for peroral application which contains S-adenosylmethi-onine-para-toluolsulfonate (SAMe) in combination with inositol and/or ino-sitol-1-phosphate and pharmaceutically acceptable excipients, in which at least one of and pharmaceutically acceptable excipients represents magnesium oxide in concentration from approximately 1.0 to approximately 10.0% of composition weight (versions), method of its obtaining, method of stabilisation of hard food and/or nutriceutic pharmaceutical composition based on SAMe-para-toluolsulfonate by application of inositol and/or inositol-1-phosphate, application of SAMe-para-toluolsulfonate in combination with inositol and/or inositol-1-phosphate for obtaining composition for treatment of depressive states and panic syndromes.

Traditional chinese medications for treatment of depression, their composition, method of preparation and treatment / 2426553
Invention relates to pharmaceutical industry, in particular to medications for treatment of depression. Traditional Chinese medication for treatment of depression. Method of preparing traditional Chinese medication for treatment of depression. Product. Pharmaceutical composition for treatment of depression. Method of preparing pharmaceutical composition (versions). Application of traditional Chinese medication in production of medications for treatment of depression. Application of product for production of medication for treatment of depression. Method of depression treatment (versions).

Tranquilliser and functional foodstuff / 2446793
There are offered an anxiolytic and/or antidepressant drug which contains vitamin K2 in the amount of 10 mcg to 100 mcg as an active component, a food additive for the same application and an appropriate method of treating.

Pharmaceutical composition for treating anxiety / 2444369
Invention refers to pharmaceutical industry, particularly to a composition for treating anxiety disorder. The pharmaceutical composition for treating anxiety disorder containing ginsenoside having Rg1 and Rb1; and a glycyrrhizic acid derivative being specified in a group consisting of glycyrrhizic acid, glycyrrhetinic acid and their combination taken in specific proportions. The pharmaceutical composition for treating anxiety disorder containing ginseng and liquorice taken in certain proportions.

Method of individual psychologic rehabilitation of patients with prosthetic heart valves / 2444288
Invention relates to medicine, cardiology and cardiac surgery, and can be used for psychological rehabilitation of patients with prosthetic heart valves (PHV). Method includes studying index of development of anxious disorders in pre-operational and post-operational periods and carrying out procedures for patients who have undergone cardiosurgical operations, including drug therapy. In determination of anxiety higher level is considered to be from 31 points and higher, additionally performed are point massage and muscular relaxation successively with groups of muscles of arms, forearms, face, neck, shoulder girdle, abdomen, hips, ankles and feet. Relaxation with each group of muscles is performed for 5-10 seconds 2-3 times per week.

Composition for injections based on crystalline β-modification of 7-brom-1,3-dihydro-5-(2-chlorphenyl)-2h-1,4-benzodiazepin-2-one exhibiting tranquilising action and method for preparing it / 2440120
Group of inventions relates to medicine, in particular to pharmacy. A composition for injections exhibiting tranquilising action contains the ingredients in the following proportions, wt %: crystalline β-modification of 7-brom-1,3-dihydro-5-(2-chlorphenyl)-2H-1,4-benzodiazepin-2-one - 0.05-0.15, polyvinylpyrrolidone - 0.50-1.20, "Tween-80" - 2.00-10.00, glycerine - 5.00-15.00, sodium pyrosulphite - 0.30-1.20, sodium hydrate solution - to pH 6.0-7.5, water - the rest. A method for preparing the composition consist in the fact that "Tween-80" and glycerine are mixed, heated to 70-90°C, and crystalline β-modification of 7-brom-1,3-dihydro-5-(2-chlorphenyl)-2H-1,4-benzodiazepin-2-one is dissolved. The prepared mixture is poured in the mixed aqueous solution of sodium pyrosulphite and polyvinylpyrrolidone heated to 40-90°C, cooled to room temperature, filtered, reduced to pH 6.0-7.5 with sodium hydrate solution, bottled and sterilised.

Mglur5 modulators / 2439068
Described are novel compounds of general formula I:

Agent showing serotonin 5-ht<sub>3</sub>-receptor antagonist properties

Agent showing serotonin 5-ht₃-receptor antagonist properties / 2438669
What is offered is a biologically active substance showing 5-HT3-serotonin receptor antagonist properties, 1-piperidinopropyl-2-(4-fluorophenyl)imidazo[1,2-a]benzimidazole of formula I. The compound has been known as a local anaesthetic. There are shown evident 5-HT3-antagonist properties of the compound in the macromolar concentration equal to the reference preparation ondansetron with the compound of formula I being safer.

Crystalline beta-modification of 7-bromo-1,3-dihydro-5-(2-chlorophenyl)-2h-1,4-benzodiazepin-2-one and synthesis method thereof / 2430094
Described is a novel crystalline β-modification of 7-bromo-1,3-dihydro-5-(2-chlorophenyl)-2H-1,4-benzodiazepin-2-one (phenazepam) and synthesis method thereof, which can be used in pharmaceutical industry and medicine as a tranquilliser. Said novel crystalline β-modification of 7-bromo-1,3-dihydro-5-(2-chlorophenyl)-2H-1,4-benzodiazepin-2-one is characterised by certain interplanar spacing (A0) and corresponding intensity and parameters of the crystal lattice, given in the claims.

Method for preparing pectoinulin of artichoke tubers / 2449803
Invention refers to pharmaceutical industry, namely preparing pectoinulin of dried ground artichoke tubers (Helianthus tuberosus L.). A method for preparing pectoinulin of dried ground artichoke tubers (Helianthus tuberosus L.) by aqueous extraction of inulin with heating; further the extract is mixed, boiled off, cooled, added with 96% ethanol; the sediment is filtered, dried up to prepare an intermediate coarse fraction of inulin and water-soluble pectin; the raw materials produced by aqueous extraction are used to extract pectins by the enzymatic preparation Maxazim NNP K, filtered, boiled off, cooled, added with 96 % ethanol; the sediment is filtered, dried; the intermediate sediments of inulin and pectin are combined, powdered to produce pectoinulin.